Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

JAMA Author Interviews
18/11/2024 14 min
Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

Listen "Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)"

Descargar episodio Ver en sitio original

Episode Synopsis

Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content: Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

More episodes of the podcast JAMA Author Interviews

From the JAMA Network: JAMA Research of the Year With Editor in Chief Kirsten Bibbins-Domingo 26/12/2025
The Sequential Organ Failure Assessment (SOFA)-2 Score 29/10/2025
From the JAMA Network: Acetaminophen Use in Pregnancy and Risk of Autism 30/09/2025
From the JAMA Network: AI-Based Analysis for Parkinsonism 30/08/2025
Treatment of Complicated Staphylococcus aureus Bacteremia 13/08/2025
From the JAMA Network: Incidence and Nature of Antidepressant Discontinuation Symptoms 05/08/2025
From the JAMA Network: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 28/07/2025
Life Support and Outcomes in Patients Admitted to Intensive Care Units 14/04/2025
Increases in Invasive Group A Streptococcal Infections 07/04/2025
Preventive Health Care Among Adults Eligible for Lung Cancer Screening 02/04/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA